| Literature DB >> 27864115 |
Wen-Ji Zhang1, Yong Li2, Meng-Ning Wei1, Yao Chen1, Jian-Ge Qiu1, Qi-Wei Jiang1, Yang Yang1, Di-Wei Zheng1, Wu-Ming Qin1, Jia-Rong Huang1, Kun Wang1, Wen-Juan Zhang3, Yi-Jun Wang4, Dong-Hua Yang4, Zhe-Sheng Chen5, Zhi Shi6.
Abstract
Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer (mCRC), but the overall clinical efficacy of regorafenib remains quite limited. Combination chemotherapy is a potentially promising approach to enhance anticancer activity, overcome drug resistance, and improve disease-free and overall survival. The current study investigates the antitumor activity of regorafenib in combination with lapatinib in preclinical models of human CRC. Our results show improved antitumor efficacy when regorafenib is combined with lapatinib both in vitro and in vivo. Furthermore, pharmacokinetic analyses revealed that regorafenib and lapatinib do not influence on each plasma concentration. The finding that regorafenib in combination with lapatinib have synergistic activity warrants further clinical investigation of this beneficial combination as a potential treatment strategy for CRC patients.Entities:
Keywords: Colorectal cancer; Combination chemotherapy; Lapatinib; Regorafenib; Targeted therapy
Mesh：
Substances：
Year: 2016 PMID： 27864115 DOI： 10.1016/j.canlet.2016.11.011
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679